Azura Ophthalmics

About:

Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD.

Website: https://azuraophthalmics.com/

Top Investors: OrbiMed, Brandon Capital, Brandon BioCatalyst, Ganot Capital, TPG Biotech

Description:

Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.